GSA Capital Partners LLP Takes $127,000 Position in Cabaletta Bio, Inc. (NASDAQ:CABA)

GSA Capital Partners LLP purchased a new position in Cabaletta Bio, Inc. (NASDAQ:CABA) during the 3rd quarter, HoldingsChannel reports. The firm purchased 26,976 shares of the company’s stock, valued at approximately $127,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Sofinnova Investments Inc. increased its position in Cabaletta Bio by 184.0% in the second quarter. Sofinnova Investments Inc. now owns 1,220,400 shares of the company’s stock worth $9,129,000 after buying an additional 790,654 shares during the period. Panagora Asset Management Inc. acquired a new stake in shares of Cabaletta Bio in the 2nd quarter worth about $2,243,000. Squarepoint Ops LLC lifted its position in Cabaletta Bio by 643.3% in the 2nd quarter. Squarepoint Ops LLC now owns 315,379 shares of the company’s stock valued at $2,359,000 after purchasing an additional 272,948 shares during the last quarter. E Fund Management Co. Ltd. boosted its stake in Cabaletta Bio by 1,610.1% during the 2nd quarter. E Fund Management Co. Ltd. now owns 286,424 shares of the company’s stock valued at $2,142,000 after purchasing an additional 269,675 shares during the period. Finally, Victory Capital Management Inc. grew its position in Cabaletta Bio by 70.7% in the 2nd quarter. Victory Capital Management Inc. now owns 634,217 shares of the company’s stock worth $4,744,000 after purchasing an additional 262,594 shares during the last quarter.

Analyst Upgrades and Downgrades

CABA has been the subject of several analyst reports. Wells Fargo & Company reduced their price objective on Cabaletta Bio from $20.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. UBS Group started coverage on Cabaletta Bio in a research report on Thursday, October 10th. They set a “buy” rating and a $10.00 price target for the company. William Blair reissued an “outperform” rating on shares of Cabaletta Bio in a report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Cabaletta Bio in a report on Friday, November 15th. Finally, Evercore ISI lowered their target price on shares of Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday, August 12th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cabaletta Bio presently has a consensus rating of “Buy” and an average price target of $27.30.

Cabaletta Bio Price Performance

CABA stock opened at $2.29 on Tuesday. The firm has a market cap of $111.94 million, a PE ratio of -1.07 and a beta of 2.42. Cabaletta Bio, Inc. has a 12 month low of $1.76 and a 12 month high of $26.35. The firm has a 50 day simple moving average of $4.00 and a 200 day simple moving average of $6.43.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.